MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team discuss how side effects of SCLC treatment and patient performance status impact treatment selection and prognosis, and the potential for molecular classification to determine future treatment options

 The multidisciplinary team:

• Medical oncologist: Dr Barbara Melosky, University of British Columbia, Vancouver, Canada
• Pulmonologist: Dr Christine Argento, Johns Hopkins University, Baltimore, MD

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Jazz Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncology.com/cme/mdt-continuing-momentum-in-sclc-second-line-and-novel-therapies/